MedTrace Logo

STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY)

NCT02306577 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2015-06-03

No results posted yet for this study

Summary

The SINNR study will evaluate the virologic efficacy (viral load \<50 copies/mL)and safety of STRIBILD administered for 48 weeks to HIV-infected current or recent illicit drug users.

Conditions

  • HIV
  • Illicit Drug User

Interventions

DRUG

STRIBILD

Taking oral 1 STRIBILD tablet once a day for 48 weeks

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Regina General Hospital

    collaborator OTHER

  • Vancouver Infectious Diseases Centre

    lead OTHER

Principal Investigators

  • Brian Conway, MD · Vancouver ID Research and Care Centre Society

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-04-30
Completion
2016-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02306577 on ClinicalTrials.gov